Head-to-head evidence
ALIA-1758 vs Sabirnetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ALIA-1758
Developed by AbbVie
NCT06406348 · Phase 1 · completed
The trial was randomized and blinded against placebo, but it was conducted in healthy volunteers purely to check safety and dosing rather than cognitive or disease benefit, and no results have been posted yet.
Sabirnetug
Developed by Acumen Pharmaceuticals
NCT04931459 · Phase 1 · completed
The trial was randomized and blinded against placebo, but its main purpose was to check safety, tolerability and drug levels in early-phase dosing cohorts rather than to prove a clinical benefit. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALIA-1758's landscape · Sabirnetug's landscape